{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T17:33:48Z","timestamp":1773509628043,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,15]],"date-time":"2016-08-15T00:00:00Z","timestamp":1471219200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010109","name":"Medical University of Graz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s11011-016-9882-2","type":"journal-article","created":{"date-parts":[[2016,8,15]],"date-time":"2016-08-15T06:19:32Z","timestamp":1471241972000},"page":"155-161","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas"],"prefix":"10.1007","volume":"32","author":[{"given":"Verena","family":"Schwetz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosaria","family":"Librizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Trummer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Theiler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Stiegler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Pieber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Obermayer-Pietsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Pilz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,15]]},"reference":[{"key":"9882_CR1","doi-asserted-by":"crossref","unstructured":"Auriemma RS, Granieri L, Galdiero M, Simeoli C, Perone Y, Vitale P, Pivonello C, Negri M, Mannarino T, Giordano C, Gasperi M, Colao A, Pivonello R (2013) Effect of cabergoline on metabolism in prolactinomas. Neuroendocrinology 98(4):299\u2013310","DOI":"10.1159\/000357810"},{"key":"9882_CR2","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/edrv.22.6.0451","volume":"22","author":"N Ben-Jonathan","year":"2001","unstructured":"Ben-Jonathan N, Hnasko R (2001) Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 22:724\u2013763","journal-title":"Endocr Rev"},{"key":"9882_CR3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.tem.2006.02.005","volume":"17","author":"N Ben-Jonathan","year":"2006","unstructured":"Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR (2006) Focus on prolactin as a metabolic hormone. Trends in Endocrinology and Metabolism: TEM 17:110\u2013116","journal-title":"Trends in Endocrinology and Metabolism: TEM"},{"key":"9882_CR4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11102-010-0277-9","volume":"14","author":"K Berinder","year":"2011","unstructured":"Berinder K, Nystrom T, Hoybye C, Hall K, Hulting AL (2011) Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 14:199\u2013207","journal-title":"Pituitary"},{"key":"9882_CR5","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/0026-0495(95)90041-1","volume":"44","author":"AH Cincotta","year":"1995","unstructured":"Cincotta AH, Meier AH (1995) Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus). Metab Clin Exp 44:1349\u20131355","journal-title":"Metab Clin Exp"},{"key":"9882_CR6","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1517\/13543784.8.10.1683","volume":"8","author":"AH Cincotta","year":"1999","unstructured":"Cincotta AH, Meier AH, Cincotta M Jr (1999) Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opinion on Investigational Drugs 8:1683\u20131707","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"9882_CR7","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/cen.12204","volume":"79","author":"A Ciresi","year":"2013","unstructured":"Ciresi A, Amato MC, Guarnotta V, Lo Castro F, Giordano C (2013) Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin Endocrinol 79:845\u2013852","journal-title":"Clin Endocrinol"},{"key":"9882_CR8","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1055\/s-0032-1321832","volume":"44","author":"LF Assuncao Alves Rodrigues de","year":"2012","unstructured":"de Assuncao Alves Rodrigues LF, Campos SM, Miranda PA, Bizzi MF, do Amaral PH S, AV G, Ribeiro-Oliveira A (2012) Prolactinoma: a condition associated with hypoadiponectinemia. Horm Metab Res 44:832\u2013838","journal-title":"Horm Metab Res"},{"key":"9882_CR9","doi-asserted-by":"crossref","unstructured":"dos Santos Silva CM, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC & Gadelha MR (2011) BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring, Md.) 19:800\u2013805","DOI":"10.1038\/oby.2010.150"},{"key":"9882_CR10","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/humrep\/14.2.285","volume":"14","author":"U Fahy","year":"1999","unstructured":"Fahy U, Hopton MI, Hartog M, Bolton CH, Hull MG (1999) The lipoprotein profile of women with hyperprolactinaemic amenorrhoea. Human Reproduction (Oxford, England) 14:285\u2013287","journal-title":"Human Reproduction (Oxford, England)"},{"key":"9882_CR11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1023\/B:PITU.0000004800.57449.67","volume":"6","author":"DJ Flint","year":"2003","unstructured":"Flint DJ, Binart N, Kopchick J, Kelly P (2003) Effects of growth hormone and prolactin on adipose tissue development and function. Pituitary 6:97\u2013102","journal-title":"Pituitary"},{"key":"9882_CR12","doi-asserted-by":"crossref","unstructured":"Inancli SS, Usluogullari A, Ustu Y, Caner S, Tam AA, Ersoy R & Cakir B (2013) Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma. Endocrine 44(1):193\u2013199","DOI":"10.1007\/s12020-012-9857-y"},{"key":"9882_CR13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF00745135","volume":"13","author":"R Landgraf","year":"1977","unstructured":"Landgraf R, Landraf-Leurs MM, Weissmann A, H\u00f6rl R, von Werder K, Scriba PC (1977) Prolactin: a diabetogenic hormone. Diabetologia 13:99\u2013104","journal-title":"Diabetologia"},{"key":"9882_CR14","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1210\/jc.2002-021137","volume":"88","author":"C Ling","year":"2003","unstructured":"Ling C, Svensson L, Oden B, Weijdegard B, Eden B, Eden S, Billig H (2003) Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab 88:1804\u20131808","journal-title":"J Clin Endocrinol Metab"},{"key":"9882_CR15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, FF C, AR H, DL K, VM M, JA S, JA W, Endocrine Society (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273\u2013288","journal-title":"J Clin Endocrinol Metab"},{"key":"9882_CR16","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1365-2265.2007.02973.x","volume":"67","author":"EC Naliato","year":"2007","unstructured":"Naliato EC, Violante AH, Caldas D, Lamounier Filho A, Loureiro CR, Fontes R, Schrank Y, Souza RG, Costa PL, Colao A (2007) Body fat in nonobese women with prolactinoma treated with dopamine agonists. Clin Endocrinol 67:845\u2013852","journal-title":"Clin Endocrinol"},{"key":"9882_CR17","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/BF03345636","volume":"31","author":"EC Naliato","year":"2008","unstructured":"Naliato EC, Violante AH, Gaccione M, Caldas D, Lamounier Filho A, Loureiro CR, Fontes R, Schrank Y, Costa FS, Colao A (2008) Body fat in men with prolactinoma. J Endocrinol Investig 31:985\u2013990","journal-title":"J Endocrinol Investig"},{"key":"9882_CR18","first-page":"12","volume":"26","author":"A Tchernof","year":"2000","unstructured":"Tchernof A, Poehlman ET, Despres JP (2000) Body fat distribution, the menopause transition, and hormone replacement therapy. Diabete Metab 26:12\u201320","journal-title":"Diabete Metab"},{"issue":"3","key":"9882_CR19","first-page":"1705","volume":"1974","author":"J Tourniaire","year":"1974","unstructured":"Tourniaire J, Pallo D, Pousset G, Bizollon C, Bachelot I (1974) Diminished glucose tolerance and hyperinsulinism due to prolactin secreting adenoma. Nouv Press Med 1974(3):1705\u20131707","journal-title":"Nouv Press Med"},{"key":"9882_CR20","doi-asserted-by":"crossref","first-page":"E271","DOI":"10.1152\/ajpendo.90920.2008","volume":"297","author":"H Wang","year":"2009","unstructured":"Wang H, Eckel RH (2009) Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab 297:E271\u2013E288","journal-title":"Am J Physiol Endocrinol Metab"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-016-9882-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11011-016-9882-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-016-9882-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-016-9882-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T03:22:47Z","timestamp":1589685767000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11011-016-9882-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,15]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["9882"],"URL":"https:\/\/doi.org\/10.1007\/s11011-016-9882-2","relation":{},"ISSN":["0885-7490","1573-7365"],"issn-type":[{"value":"0885-7490","type":"print"},{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,15]]}}}